associated with an increased risk of developing hepatotoxicity (Table 1) . However, GST M1 null genotype was associated with a 3.28-fold increased risk of hepatotoxicity, with a trend toward significance (P ¼ 0.06).
There was no significant difference in achieving or time to achieving CR in the group that developed hepatotoxicity and the group that did not (median time to CR: 43 versus 42 days, respectively). The 3-year Kaplan-Meier estimate of OS, EFS and DFS in the group that did not develop hepatotoxicity and the group that did was 95.7472.94, 81.1476.57, 81.3176.95 and 96.5573.39, 96.5573.39, 10070, respectively. Statistical analysis by log-rank test of the survival curves between these two groups did not show a statistically significant difference for OS, EFS or DFS. There was also no statistically significant evidence of a difference in EFS or DFS among patients based on the genetic polymorphisms that were analyzed.
In this series, of the 73 patients who achieved CR, six patients subsequently relapsed. It was of interest to note that none of these relapsed cases had any evidence of hepatotoxicity. Although this observation did not attain statistical significance, there was a trend to a better DFS in the group that developed hepatotoxicity (P ¼ 0.085).
Other adverse events seen with this regimen have been reported earlier. 8 The majority of such adverse events were mild and did not warrant discontinuing therapy. There were no sudden deaths attributable to a cardiac event in this series of patients, and on follow-up there were no documented second malignancies.
This study shows that when single agent As 2 O 3 is used for induction, consolidation and maintenance in the treatment of newly diagnosed cases of APL, it is associated with minimal hepatic toxicity and is well tolerated. It is also associated with durable remissions, which are comparable to conventional ATRA plus chemotherapy regimens. 8 There are no published data commenting on the impact of hepatotoxicity on long-term outcome. In our series, the incidence of hepatotoxicity had no impact on achieving CR nor did it adversely affect OS, EFS or DFS.
The statistically significant increased risk for patients with the homozygous mutation of MTHFR 1298 (C/C) to develop hepatotoxicity suggests that it alters the biotransformation of As 2 O 3 . We hypothesize that polymorphisms of the MTHFR gene have an effect on As 2 O 3 methylation, which is an important pathway of biotransformation of this substance. This alteration in biotransformation possibly leads to quantitative and qualitative differences in the methylated intermediaries that are generated, which in turn could have a bearing on the toxicity profile of As 2 O 3 . A trend toward an increased risk for hepatotoxicity was also noted in this series with the GST M1 null phenotype. It has been noted that this polymorphism is also associated with alterations in the methylation of inorganic arsenic. 4 A better understanding of the pathways of biotransformation of As 2 O 3 and the impact of genetic polymorphisms on its biotransformation could be useful in predicting efficacy and toxicity. Although in this series of newly diagnosed patients the toxicity profile was mild and their prediction would not have contributed significantly to the clinical outcome, it could potentially be useful in a high-risk group such as the elderly and multiply relapsed patients. Beyond prediction of toxicity, a better understanding of altered methylated derivatives generated owing to these polymorphisms has the potential to identify metabolic derivatives that are more effective with less toxicity compared to inorganic As 2 A causal link between persistent activation of a lymphoid compartment and the occurrence of lymphoma is best established in extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type. The contribution of such factors to T-cell neoplasia is unclear, although immunophenotypic attributes of T-cell large granular lymphocytic leukemia (T-LGL) indicate that this disease is derived from antigen-stimulated cytotoxic T cells. 1 These attributes include the expression of natural killer (NK) -cell-associated receptors (NKRs), a group of proteins broadly divided into the CD94/ NKG2 heterodimer and the killer cell immunoglobulin-like receptor (KIR) types that are normally present on NK-cells and a subset of memory cytotoxic T cells.
2 Non-hepatosplenic gd Tcell lymphomas are another group of cytotoxic T-cell malignancies that have been associated with chronic antigen exposure. 3 The role of antigenic stimulation in the etiology of hepatosplenic T-cell lymphoma (HSTCL), a disorder of cytotoxic T cells that is frequently, but not exclusively, of gd lineage, is unclear. 4 There have been few studies of the NKR expression in this disease. Given the possible contribution of antigenic stimulation to the development of cytotoxic T-cell malignancies, we examined NKR expression in a group of seven HSTCL cases.
The clinical and pathologic features of the seven studied HSTCL cases are summarized in Table 1 . Paraffin immunohistochemistry performed on the bone marrow biopsies using antibodies to CD3 and the cytotoxic granule proteins TIA-1 and granzyme B revealed features diagnostic of involvement in all cases ( Figure 1 ). In cases 4 and 5, renal transplantation had been performed 7 and 6 years before the diagnosis of HSTCL, respectively. Splenomegaly was present in six patients, and palliative splenectomy in one (case 6) revealed diffuse red pulp infiltration by cytologically atypical cytotoxic T cells (Figure 1 ). In the remaining patient, the spleen had been removed during renal transplant surgery; hepatomegaly in this case was documented at autopsy.
Flow cytometric immunophenotyping (FCIP) studies using antibodies to T-and NK-cell-associated antigens were performed on involved peripheral blood (n ¼ 3; cases 3, 4, and 5) or bone marrow (n ¼ 4) aspirate specimens. 1 In all HSTCL cases, an immunophenotypically aberrant CD3-positive T-cell population was detected; three expressed ab TCR, the remaining four were gd TCR positive (Table 1) . In six cases, the abnormal T cells showed complete absence of CD5 expression; diminished CD7 expression was also frequent (n ¼ 4). Four HSTCLs were CD8 positive by FCIP; all showed either dim or partial expression of this antigen. In three of these cases, CD8 expression was also studied by paraffin immunohistochemistry and none were positive by this technique; these differences likely reflect the greater sensitivity of FCIP.
NK-cell-associated receptors expression was studied by a three-color FCIP strategy that allowed for specific gating on the cell population of interest (Table 1) .
1 CD94 was expressed by all of the HSTCL with the exception of one of the gd HSTCLs (case 5). Of the six CD94-positive HSTCL, four showed dim surface staining for this antigen (Figure 2a) , including two of the gd TCRpositive cases. As normal Vd1 gd T cells, the compartment from which gd HSTCL arises, show bright surface CD94 staining, the dim or absent CD94 expression observed in three of the four gd HSTCL cases appears to be aberrant. The expression of NKG2A and/or NKG2C, antigens that pair with CD94 to form HLA-E receptor complexes, 2 was not assessed, as these studies have not been found to be of utility in routine clinical flow cytometry practice. CD161 was expressed in six of the seven HSTCLs and none of the HSTCLs expressed CD57 (Figure 2a) .
All of the HSTCL were KIR positive. Coincident expression of multiple KIR isoforms was detected in two of the three ab HSTCLs and three of the four gd HSTCLs (Table 1 and Figure 2b ). In the remaining two cases, a single KIR isoform was expressed. In normal ab cytotoxic T cells, KIR antigens are found exclusively on cells with a memory phenotype. 7 Hence, the uniform expression of these antigens in HSTCL suggests that it is a disease of memory T cells. KIR-positive normal ab and gd T cells, however, typically express a single isoform; therefore the frequent expression of multiple KIRs in HSTCL was unexpected. This unusual pattern of multiple KIR antigen expression in HSTCL suggests a commonality between the ab and gd types and may prove to be a distinguishing feature of the disease. In an immunohistochemical study of CD94 and KIR expression in a group 15 extranodal cytotoxic T-cell lymphomas by Haedicke et al., 5 the single case found to coexpress CD94 and multiple KIRs (CD158a and CD158b) was a gd HSTCL. Literature regarding KIR expression in other bona fide gd T-cell lymphoproliferative disorders is scarce. One report contained two gd Tcell disorders (T-LGL and gd T-cell lymphoproliferative disorder, unclassified), both of which were KIR negative. 6 Among ab cytotoxic T-cell disorders, KIR expression has primarily been addressed in T-LGL. Of 16 published KIR-positive ab T-LGL cases, only two expressed multiple isoforms (both were CD158a and CD158b positive). 1, 6 The distinctive pattern of KIR expression in the HSTCL may also provide insights into the disease pathogenesis. As KIR expression in ab T cells is induced by chronic antigenic stimulation, 7 the expression of multiple KIR isoforms could be indicative of a response to prolonged unbridled stimulatory signals. Interestingly, two of the four studied gd HSTCL occurred in patients with renal allografts, tissues that have been Figure 2 (a) A multicolor flow cytometric immunophenotyping gating strategy is used to selectively gate on the CD3-and CD56-positive HSTCL cells (case 1, upper panel, highlighted green) and demonstrate that they coexpress CD94 (lower left) and lack CD57 (lower right). Note that the cells show dim staining with antibodies to CD94, with a median fluorescent intensity near the horizontal line representing the negative cutoff established with an antibody isotype control. Similar CD94 staining intensity was seen in cases 3, 4 and 6. (b) The multicolor gating strategy is used to selectively gate on the CD3-positive HSTCL cells in case 2, which aberrantly coexpress CD16 (upper panel). As seen in the lower panels, these studies demonstrate that the neoplastic cells uniformly coexpress the KIR antigens CD158a, CD158b, and CD158e (also referred to as p70) (FITC, fluorescein isothiocyanate; PE, phycoerythrin; PerCP, peridinin chlorophyll-a protein).
previously shown to produce high levels of MICA and MICB, stress-induced MHC-I-related proteins that are known to stimulate gd T cells. 8 KIR expression may not only be a sign of prior antigenic stimulation, but could also be implicated in neoplastic transformation. In normal cytotoxic ab-T cells, KIRs have pleiotropic effects, both raising the threshold required for cytolytic activity and promoting cell survival. 7 These multiple functions are required, as these cells contain multiple cytotoxic effector proteins and have limited proliferative potential. In contrast to normal KIR-positive T cells, HSTCL usually do not express perforin and granzyme B. Furthermore, given the aggressive clinical behavior of HSTCL, it is likely that the malignant cells are actively proliferating. It is an intriguing possibility that the discrepancy between the expression of KIRs and cytotoxic effector proteins in HSTCL reflects alterations in signal transduction or gene expression pathways that allow the neoplastic cells to inappropriately express KIRs and thereby acquire resistance to activation-induced cell death. Additional investigations including study of KIR gene expression and tumor-host interactions may allow for further characterization of these cells to firmly establish that they are derived from memory T cells and provide other insights into the pathogenesis of these unique, aggressive neoplasms, which may lead to development of novel therapeutic strategies. This letter is addressed to the paper by Gabert et al., 1 in which the Europe Against Cancer (EAC) program has proposed a standardized real-time quantitative polymerase chain reaction (RQ-PCR) protocol designed for studies of minimal residual disease (MRD) in fusion transcript bearing leukemia. Although this protocol has been established in the frame of molecular follow-up, its very practical use would prompt molecular labs to choose it as tool for diagnostic purposes, at least for BCR-ABL screening in chronic myelogenous leukemia (CML). This is an inappropriate approach as false-negative results at diagnosis of a CML may be encountered with the use of this protocol. Indeed, we report hereby three Philadelphia (Ph þ ) CML patients with a major breakpoint cluster region (M-bcr) rearrangement detectable by fluorescent in situ hybridization (FISH) and classical qualitative RT-PCR but not by RQ-PCR with the use of the standardized EAC protocol.
All three patients had clinical and biological features highly suggestive for CML. Bone marrow examination of the third patient also revealed 30% blasts with myeloid antigens. Cytogenetic analyses performed on bone marrow samples from patients 1 and 2 disclosed a 46,XX,t(9;22)(q34;q11) karyotype in 23 mitoses and a 46,XY,t(9;22)(q34;q11) karyotype in 30 mito- Abbreviations: BM, bone marrow; Cyto, cytogenetic findings; Dim, antigen expressed with staining intensity within 1 log of isotype control;.N/A, results not available; Neg, antigen not expressed; Pos, antigen expressed; TCR, T-cell receptor heterodimer expressed; Tg PCR, polymerase chain reaction using TCR g chain gene specific primers; Vb flow, flow cytometric method using antibodies to specific TCR-Vb families. a By fluorescence in situ hybridization.
